Close Menu

NEW YORK – Biocept reported after the close of the market on Thursday that its third quarter revenues more than quadrupled year over year driven by its current offering of molecular COVID-19 testing services.

For the three months ended Sept. 30, the San Diego-based liquid biopsy company posted $6.6 million in revenues compared to $1.5 million in Q3 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.